0
Original Research: PULMONARY VASCULAR DISEASE |

Prognostic Models for Selecting Patients With Acute Pulmonary Embolism for Initial Outpatient Therapy*

David Jiménez, MD; Roger D. Yusen, MD, FCCP; Remedios Otero, MD; Fernando Uresandi, MD; Dolores Nauffal, MD; Elena Laserna, MD; Francisco Conget, MD; Mikel Oribe, MD; Miguel A. Cabezudo, MD; Gema Díaz, MD
Author and Funding Information

*From the Respiratory Department (Dr. Jiménez), Ramón y Cajal Hospital, Madrid, Spain; Division of Pulmonary and Critical Care Medicine (Dr. Yusen), Washington University School of Medicine, St. Louis, MO; Respiratory Department (Drs. Otero and Laserna), Virgen del Rocío Hospital, Sevilla, Spain; Respiratory Department (Dr. Uresandi), Cruces Hospital, Bizkaia, Spain; Respiratory Department (Dr. Nauffal), La Fe Hospital, Valencia, Spain; Respiratory Department (Dr. Conget), Lozano Blesa Hospital, Zaragoza, Spain; Respiratory Department (Dr. Oribe), Galdakao Hospital, Galdakao, Spain; Respiratory Department (Dr. Cabezudo), Oviedo Hospital, Oviedo, Spain; and Respiratory Department (Dr. Diaz), Zarzuela Hospital, Madrid, Spain.

Correspondence to: David Jiménez, MD, Respiratory Department. Ramón y Cajal Hospital, Department of Medicine, Alcalá de Henares University, 28034 Madrid, Spain 913368314; e-mail: djc_69_98@yahoo.com



Chest. 2007;132(1):24-30. doi:10.1378/chest.06-2921
Text Size: A A A
Published online

Objective: To assess the performance of two prognostic models in predicting short-term mortality in patients with pulmonary embolism (PE).

Subjects and methods: We compared the test characteristics of two prognostic models for predicting 30-day outcomes (mortality, thromboembolic recurrences, and major bleeding) in a cohort of 599 patients with objectively confirmed PE. Patients were stratified into the PE severity index (PESI) risk classes I-V and the Geneva low-risk and high-risk strata. We compared the discriminatory power of both prognostic models.

Results: The PESI classified fewer patients as low risk (strata I and II) [36%; 216 of 599 patients; 95% confidence interval (CI), 32 to 40%] compared to the Geneva prediction rule (84%; 502 of 599 patients; 95% CI, 81 to 87%) [p < 0.0001]. Using either prediction rule, the low-risk groups showed statistically relevant 30-day mortality difference (PESI, 0.9%; 95% CI, 0.3 to 2.2; vs Geneva, 5.6%; 95% CI, 3.6 to 7.6) [p < 0.0001], although nonfatal recurrent venous thromboembolism or major bleeding rates were statistically similar (PESI, 2.8%; 95% CI, 0.6 to 5.0%; vs Geneva, 4.2%; 95% CI, 2.4 to 5.9%). The area under the receiver operating characteristic curve was higher for the PESI (0.76; 95% CI, 0.69 to 0.83) than for the Geneva score (0.61; 95% CI, 0.51 to 0.71) [p = 0.002].

Conclusions: The PESI quantified the prognosis of patients with PE better than the Geneva score. This study demonstrated that PESI can select patients with very low adverse event rates during the initial days of acute PE therapy and assist in selecting patients for treatment in the outpatient setting.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543